Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9,977 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical Impact of Preoperative Prognostic Nutritional Index in Surgical Patients With Pancreatic Cancer Treated With Perioperative Adjuvant Chemotherapy.
Kawahara S, Aoyama T, Murakawa M, Kanemoto R, Takahashi D, Kamioka Y, Hashimoto I, Maezawa Y, Kobayashi S, Ueno M, Yamamoto N, Oshima T, Yukawa N, Rino Y, Saito A, Morinaga S. Kawahara S, et al. Among authors: kobayashi s. Anticancer Res. 2024 Apr;44(4):1711-1718. doi: 10.21873/anticanres.16970. Anticancer Res. 2024. PMID: 38537971
Severe inflammation in the background liver cirrhosis correlates with the development of poorly differentiated HCC in HCV-associated liver cirrhosis.
Tarao K, Miyakawa K, Miyagi Y, Ohkawa S, Morinaga S, Oshige K, Yamamoto N, Ueno M, Kobayashi S, Kameda R, Tamai S, Nakamura Y, Endo Y, Kameda Y, Okudaira M. Tarao K, et al. Among authors: kobayashi s. Intern Med. 2012;51(18):2495-501. doi: 10.2169/internalmedicine.51.7744. Epub 2012 Sep 15. Intern Med. 2012. PMID: 22989817 Free article.
Inflammation in background cirrhosis evokes malignant progression in HCC development from HCV-associated liver cirrhosis.
Tarao K, Ohkawa S, Miyagi Y, Morinaga S, Ohshige K, Yamamoto N, Ueno M, Kobayashi S, Kameda R, Tamai S, Nakamura Y, Miyakawa K, Kameda Y, Okudaira M. Tarao K, et al. Among authors: kobayashi s. Scand J Gastroenterol. 2013 Jun;48(6):729-35. doi: 10.3109/00365521.2013.782064. Epub 2013 Apr 5. Scand J Gastroenterol. 2013. PMID: 23556482
Risk factors for 6-month continuation of S-1 adjuvant chemotherapy for resected pancreatic cancer.
Aoyama T, Katayama Y, Murakawa M, Asari M, Kanazawa A, Higuchi A, Shiozawa M, Kobayashi S, Ueno M, Morimoto M, Ohkawa S, Akaike M, Yamamoto N, Yoshikawa T, Rino Y, Masuda M, Morinaga S. Aoyama T, et al. Among authors: kobayashi s. Cancer Chemother Pharmacol. 2014 Dec;74(6):1235-40. doi: 10.1007/s00280-014-2601-y. Epub 2014 Oct 9. Cancer Chemother Pharmacol. 2014. PMID: 25297990
Safety and feasibility of S-1 adjuvant chemotherapy for pancreatic cancer in elderly patients.
Aoyama T, Katayama Y, Murakawa M, Atsumi Y, Yamaoku K, Kanazawa A, Higuchi A, Shiozawa M, Kobayashi S, Ueno M, Morimoto M, Yamamoto N, Oshima T, Yoshikawa T, Rino Y, Masuda M, Morinaga S. Aoyama T, et al. Among authors: kobayashi s. Cancer Chemother Pharmacol. 2015 Jun;75(6):1115-20. doi: 10.1007/s00280-015-2736-5. Epub 2015 Mar 29. Cancer Chemother Pharmacol. 2015. PMID: 25821166
9,977 results